France Infectious Disease Therapeutics Market Report 2022 to 2030

France Infectious Disease Therapeutics Market Analysis

$ 3999

By 2030, it is anticipated that the France infectious disease therapeutics market will reach a value of $4.29 Bn from $3.3 Bn in 2022, growing at a CAGR of 3.4% during 2022-2030. The Infectious Disease Therapeutics in France is dominated by a few domestic pharmaceutical companies such as BioMérieux, Sanofi and Institut Mérieux. The Infectious Disease Therapeutics market in France is segmented into different therapeutic areas and different diseases type. The major factors affecting the France infectious disease therapeutics market are the increasing disease burden of communicable diseases like TB, hepatitis, and COVID-19 and the lack of healthcare funding for infectious diseases treatment in various areas of France.

ID: IN10FRPH038 CATEGORY: Pharmaceuticals GEOGRAPHY: France AUTHOR: Dr. Vishwa Modhia

Buy Now

France Infectious Disease Therapeutics Analysis Summary

By 2030, it is anticipated that the France infectious disease therapeutics market will reach a value of $4.29 Bn from $3.3 Bn in 2022, growing at a CAGR of 3.4% during 2022-2030.

France is a developed country in Western Europe with various overseas territories and islands on other continents and in the Indian, Pacific, and Atlantic oceans. Among the infectious diseases in France, widespread ongoing transmission of a respiratory illness caused by the novel coronavirus (COVID-19) was occurring throughout France; as of December 2022, France has reported a total of 37,252,086 cases of COVID-19. the French National Authority for Health (HAS), which provides guidance on the use of new treatments within the healthcare system. France offers universal healthcare, which covers 77.4 % of healthcare costs. The remainder of the payments are either out-of-pocket or covered by volunteer health insurance. France's government spends 12.2 % of its GDP on healthcare in 2020.

France Infectious Disease Therapeutics Analysis

Market Dynamics

Market Growth Drivers Analysis

Significant investment has been made in the research and development of infectious disease medicines in France, particularly in the areas of antibiotic resistance, HIV/AIDS, and hepatitis C. In France, two organisations are actively participating in infectious disease treatment research: the French National Institute of Health and Medical Research (INSERM) and the French Agency for Research on AIDS and Viral Hepatitis (ANRS). Several advances in infectious illness therapies have occurred in France in recent years. For example, various novel antiviral medications have been developed to treat hepatitis C, including sofosbuvir and ledipasvir.

In addition, novel antibiotics, such as ceftazidime-avibactam, have been developed to fight antibiotic-resistant infections. France has a talented and productive workforce, as well as a changing demography. The quality of infrastructure and public service facilities improves the country's corporate operations. These aspects could boost France's infectious disease therapeutics market.

Market Restraints

Developing new pharmaceuticals and therapies necessitates adhering to regulatory rules established by organisations such as the French National Agency for Medicines and Health Products Safety (ANSM). These requirements can be complicated and time-consuming, resulting in delays and higher expenses. Drug companies may be hesitant to engage in researching novel medicines if they fear the end result will be unprofitable due to a lack of patent protection or competition from generic pharmaceuticals. These factors may deter new entrants into the France infectious disease therapeutics market.

Competitive Landscape

Key Players

Sanofi - Sanofi is a leading French pharmaceutical company that develops and manufactures a range of infectious disease therapeutics, including vaccines, antibiotics, and antivirals
Institut Mérieux - Institut Mérieux is a French biopharmaceutical company that specializes in the development and production of vaccines and immunotherapies
BioMérieux - BioMérieux is a French biotechnology company that develops and manufactures diagnostic tests for infectious diseases
Vaxxel - Vaxxel is a French biotechnology company that develops vaccines for infectious diseases. The company's lead product, a vaccine for pertussis (whooping cough), is currently in clinical trials
Innate Pharma - Innate Pharma is a French biotechnology company that develops immunotherapies for cancer and infectious diseases

Recent Notable Updates

November 2022: Following the positive judgement of the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) on VidPrevtyn beta, the vaccine was authorised by the European Commission as a booster for the prevention of COVID-19 in adults aged 18 and over. Sanofi's VidPrevtyn Beta is a next-generation, monovalent, recombinant protein vaccine against COVID-19 based on the beta version and contains GSK's pandemic adjuvant.

Healthcare Policies and Reimbursement Scenarios

The National Agency for the Safety of Medicines (ANSM) and Health Products regulates infectious illness therapies in France. The ANSM is in charge of ensuring the safety, effectiveness, and high quality of all medications and medical equipment, particularly those used to treat infectious diseases. In order to be approved for use in France, infectious disease treatments must undergo a regulatory process that includes clinical studies and another testing to ensure their safety and efficacy. Following the approval of a product, the ANSM continues to monitor its safety and quality through post-marketing monitoring.

In France, the national health insurance system, known as the Assurance Maladie, manages the coverage of infectious disease medications. The cost of these therapies is either partially or completely reimbursed, depending on the patient's eligibility and the type of treatment. In France, the payment system is tier-based, with different levels of coverage depending on the severity of the sickness and the type of therapy necessary. Treatments for life-threatening infectious diseases like HIV or hepatitis C, for example, are often covered at a higher rate than treatments for less severe infections.

1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share

4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment

6. Methodology and Scope

Infectious Disease Therapeutics Segmentation

By Mode of Treatment (Revenue, USD Billion):

Vaccines
Drugs

By Applications (Revenue, USD Billion):

HIV/AIDS
Influenza
Hepatitis
Malaria
Tuberculosis
Others

By Disease Type (Revenue, USD Billion):

Viral Diseases
Bacterial Diseases
Fungal Diseases
Parasitic Diseases
Others

By Target Organism (Revenue, USD Billion):

Antibiotics
Antivirals
Antifungals
Anti-Parasitic
Others

By End User (Revenue, USD Billion):

Hospitals and Clinics
Ambulatory Care Centers
Others

Methodology for Database Creation

Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.

Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.

How Do We Get It?

Our database is created and maintained through a combination of secondary and primary research methodologies.

1. Secondary Research

With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:

Analyzing historical proprietary data collected from multiple projects.
Regularly updating our existing data sets with new findings and trends.
Ensuring data consistency and accuracy through rigorous validation processes.

With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:

Searching through academic conferences, published research, citations, and social media platforms
Collecting and compiling diverse data to build a comprehensive and detailed database
Continuously updating our database with new information to ensure its relevance and accuracy

2. Primary Research

To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:

Collaborating with local healthcare providers, hospitals, and clinics to gather real-time data.
Conducting surveys, interviews, and field studies to collect fresh data directly from the source.
Continuously refreshing our database to ensure that the information remains current and reliable.
Validating secondary data through cross-referencing with primary data to ensure accuracy and relevance.

Combining Secondary and Primary Research

By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:

Merging historical data from secondary research with real-time data from primary research.
Conducting thorough data validation and cleansing to remove inconsistencies and errors.
Organizing data into a structured format that is easily accessible and usable for various applications.
Continuously monitoring and updating the database to reflect the latest developments and trends in the healthcare field.

Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.

To request a free sample copy of this report, please complete the form below.

We value your inquiry and offer free customization with every report to fulfil your exact research needs.

Yes, I have read the privacy policy

The National Agency for the Safety of Medicines (ANSM) and Health Products regulates infectious illness therapies in France.

In France, the national health insurance system, known as the Assurance Maladie, manages the coverage of infectious disease medications.

The Infectious Disease Therapeutics in France is dominated by a few domestic pharmaceutical companies such as BioMérieux, Sanofi and Institut Mérieux.